CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Information and referral conditionWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug2342 RISE Wiki 1.00

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D015817 Eye Infections NIH 1.00
D003231 Conjunctivitis NIH 0.71
D007249 Inflammation NIH 0.19
D014777 Virus Diseases NIH 0.12

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0000509 Conjunctivitis HPO 0.71

There is one clinical trial.

Clinical Trials


1 Recovering From Intimate Partner Violence Through Strengths and Empowerment (RISE): Tailoring and Evaluating a Patient-Centered Counseling Intervention for Women Veterans

Intimate partner violence (IPV) is a major health concern for women Veterans. IPV is associated with numerous physical and mental health conditions. VHA is implementing IPV screening programs to identify female patients who experience past-year IPV. Despite strong evidence that screening increases detection of IPV, less is established about how to intervene following IPV disclosure in health care settings, in order to improve health outcomes. Existing healthcare-based interventions result in minimal effects on health and well-being, likely because they are too brief and generic. In response, the PI has developed Recovering from IPV through Strengths and Empowerment (RISE), based on the IPV-related health care needs and preferences of women Veterans. RISE is designed to be delivered in primary care and is an individualized, variable-length, modular-based intervention that addresses - safety planning; - education on the health effects of IPV; - increasing coping skills and self-care; - enhancing social support; - making difficult decisions; and - connecting with resources. This study is aimed at refining and evaluating RISE for use with female VA patients who have experienced past-year IPV. This brief counseling intervention is intended to be administered in conjunction with primary care, as this is a frequent point of healthcare contact for women Veterans and where disclosure of IPV is most prevalent.

NCT03261700 Intimate Partner Violence Empowerment Behavioral: RISE Other: Information and referral condition

Primary Outcomes

Description: Measures change in sense of personal empowerment

Measure: Empowerment via the Personal Progress Scale Revised

Time: Change from baselineline empowerment at 10 and 14 weeks

Description: This scale is a self-report of change in general self-efficacy

Measure: Self-efficacy via the General Self-Efficacy Scale

Time: Change from baseline self-efficacy at 10 and 14 weeks

Description: Measures change in valued living, and congruence between stated values and past-week valued behavior

Measure: Valued Living Questionnaire

Time: Change from baseline congruent behaviors at 10 and 14 weeks

Description: Measures change in patient engagement in needed health care

Measure: Patient Activation Measure

Time: Change from baseline patient activation at 10 and 14 weeks

Secondary Outcomes

Description: Measures change in DSM-5 PTSD symptoms

Measure: PTSD Checklist-5

Time: Change from baseline PTSD symptoms at 10 and 14 weeks

Description: Measures change in depressive symptoms

Measure: Center for Epidemiological Studies-Depression Scale

Time: Change from baseline depression symptoms at 10 and 14 weeks

Description: Measures change in physical-health related quality of life

Measure: SF-12 Health Survey

Time: Change from baseline physical-health related quality of life at 10 and 14 weeks

Description: Measures change in physical, sexual, and psychological IPV

Measure: Conflict Tactic Scales Revised

Time: Change from baseline IPV at 10 and 14 weeks

Description: Measures change in VA and non-VA physical and mental health use and social service use

Measure: Physical, Mental and Social Service Care Use

Time: Change from baseline VA and non-VA health care and social service use at 10 and 14 weeks

Description: Measures acceptability of treatment

Measure: Client Services Questionnaire

Time: 10 weeks

Description: Measures change in somatic and physical health symptoms

Measure: Patient Health Questionnaire

Time: Change from baseline somatic and physical health symtpoms at 10 and 14 weeks

Description: Measures change in patients' behaviors to safeguard themselves against IPV

Measure: Safety Behaviors Checklist

Time: Change from baseline safety behavior use at 10 and 14 weeks

Description: Measures change in patient resilience

Measure: Connor-Davidson Resilience Scale

Time: Change from baseline resilience at 10 and 14 weeks

Description: Measures change in anxiety symtpoms

Measure: Depression Anxiety Stress Scale- Anxiety Subscale

Time: Change from baseline anxiety at 10 and 14 weeks

Description: Measures engagement and disengagement coping skills

Measure: Coping Strategies Inventory - Short Form

Time: Change from baseline coping skills at 10 and 14 weeks

Description: Semi-structured interview questions developed for the purpose of this study assess participants' perceptions of the intervention, including acceptability and feasibility, as well as barriers to treatment engagement.

Measure: Brief semi-structured interview to assess acceptability and feasibility of the intervention

Time: 10 and 14 weeks


No related HPO nodes (Using clinical trials)